TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01713153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 600 mcg misoprostol oral

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UnijectTM
Description: 10 IU oxytocin delivered intramuscularly with UnijectTM
Study: NCT01788722

Intervention type: DRUG
Intervention: Dienogest (Visanne, BAY86-5258)
Description: Patients in daily life clinical practice treatment receiving Visanne (dienogest 2mg) according to indication on the label.
Study: NCT01195922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 21 evaluable subjects will take rapamycin (sirolimus) orally once per day for 21 days. Before and after dosing tumor assessments to include: photographs, CT \& amp; PET scans will be done for tumor measurement.
Study: NCT04253522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Rehabilitation program in standard ergotherapy and cognitive training with Covirtua Software and Transcranial random noise stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Rehabilitation program in standard ergotherapy and cognitive training with Covirtua Software and Transcranial random noise stimulation
Study: NCT05976282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test
Description: The Fecal Immunochemical Test (FIT) is self-administered one-time for participants, per standard of care. This allows participants to obtain their own stool specimens from bowel movements without having a regular colorectal screening procedure in the doctor's office. Participants will use the FIT at the time of their next bowel movement and return their specimens to the laboratory by mail on the same or next day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Septin9 Test
Description: Septin9 (SEPT9) is a blood-based test that will be offered to eligible participants one-time who refused the FIT. Participants will undergo a blood draw collected by a nurse or certified phlebotomist, 90 days after their refusal of the initial offer of FIT.
Study: NCT02002403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Study: NCT02925767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 311-nm Ti:Sapphire laser
Description: Pallas, LaserOptek, South Korea

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 308-nm excimer laser
Description: XTRAC, PhotoMedex, US
Study: NCT03278015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus Gemcitabine
Description: Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine monotherapy
Description: Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 monotherapy
Description: S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
Study: NCT02707354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Probe based confocal laser endomicroscopy (Cellvizio)
Description: The probe is a miniaturized microscope in the form of a fiber which is inserted through the endoscope and brought into contact with the mucosa. It thus allows for a live virtual biopsy, that is to say, obtaining real-time microscopic virtual image of the mucosa. It requires an intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console so that two endoscopists blinded from the macroscopic and histological findings can review the data.
Study: NCT03042065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibrating Mesh nebulizer
Description: Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: jet nebulizer
Description: Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using jet nebulizer
Study: NCT04196179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG3070
Description: ANG-3070 drug product is a an immediate release oral solid. The drug product consists of a Size 00 Swedish orange capsule containing drug substance (10 mg, 50 mg, or 250 mg) with no excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG3070
Description: ANG-3070 drug product is a an immediate release oral solid. The drug product consists of a Size 00 Swedish orange capsule containing drug substance (10 mg, 50 mg, or 250 mg) with no excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: ANG-3070 placebo capsules visually match the drug product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: ANG-3070 placebo capsules visually match the drug product.
Study: NCT02207816

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Malaria Vaccine 257049 (MALARIA-055 PRI)
Description: Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria Vaccine 257049 (MALARIA-055 PRI)
Description: Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)
Description: Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)
Description: Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cell-culture rabies vaccine (MALARIA-055 PRI)
Description: Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TritanrixHepB/Hib (MALARIA-055 PRI)
Description: Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TritanrixHepB/Hib (MALARIA-055 PRI)
Description: Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TritanrixHepB/Hib (MALARIA-055 PRI)
Description: Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)
Description: Administered orally, during the MALARIA-055 study (NCT00866619).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)
Description: Administered orally, during the MALARIA-055 study (NCT00866619).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)
Description: Administered orally, during the MALARIA-055 study (NCT00866619).
Study: NCT01834066

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stem Cell
Description: Intralesional transfer of Autologous Stem cell (MNCs) per dose. 6 doses in 3 months
Study: NCT04401514

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rocking chair therapy
Description: 20 min long rocking therapy with music cure. The therapy can be extended if needed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rocking chair therapy
Description: 20 min long rocking therapy with music cure. The therapy can be extended if needed
Study: NCT04185805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet A
Description: Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet A
Description: Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet B
Description: Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet B
Description: Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
Study: NCT03150472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graft Matrix
Description: Both Graft matrix products are supplied sterile, for single use only and packed in vials or a syringe-like applicator. All products consist of the same bone graft particles with the only variants being due to different amounts per package or different containers.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Graft Matrix
Description: Both Graft matrix products are supplied sterile, for single use only and packed in vials or a syringe-like applicator. All products consist of the same bone graft particles with the only variants being due to different amounts per package or different containers.
Study: NCT02877043

Intervention type: PROCEDURE
Intervention: resection pulmonaire
Study: NCT02001857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
Description: at the end of surgery
Study: NCT01471054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex
Description: Eyes in the Ozurdex group can have a maximum total of three Ozurdex insertions in the first 12 months after enrolling into the study. The criteria for retreatment with Ozurdex are:~i.The study eye must have shown initial favorable response to prior Ozurdex implant (\>10% decrease in central macular thickness with maintenance \[change in BCVA of \<=1 line\] or improvement of visual acuity \[increase of BCVA of \>1 line\]) ii. Interval since last Ozurdex implant should be \> 4 and \< 12 months. iii. The study eye must show definite evidence of recurrence of macular edema.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Eyes in the Bevacizumab group can have a maximum total of twelve bevacizumab injections in the first year after enrolling into the study. All patients will receive 6 monthly injections after entering the study. After the sixth injection (at month 5) the interval between injections will be extended to 6 weeks if the study eye has shown initial favorable response to prior intravitreal bevacizumab.
Study: NCT01777659

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: Patients will be treated with conventional TENS (ENDOMED 684 Device, ENRAF-Nonius B.V., Rotterdam, Netherlands) for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). TENS intervention was applied as described elsewhere.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: Patients will be treated with conventional TENS (ENDOMED 684 Device, ENRAF-Nonius B.V., Rotterdam, Netherlands) for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). TENS intervention was applied as described elsewhere.
Study: NCT00854633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talactoferrin
Description: Enteral, 150 mg/kg twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, twice per day
Study: NCT05087316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biomimetic oral appliance therapy (BOAT)
Description: BOAT appliance is designed to correct maxillo-mandibular underdevelopment in both children and adults (Singh and Lipka, 2009). However, adults will only use for this study. Typically, a BOAT appliance consists of 6 patented, anterior 3-D Axial Springs™, a midline actuator (such as omega loops or screws), posterior occlusal rests, and a round labial bow (Figure 1). Patients will be trained on activation of the screw

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard hospital treatment
Description: Use of CPAP and similar methods
Study: NCT02209051

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AMNIOEXCEL
Description: Application of AMNIOEXCEL every 1-2 weeks for a period of 6 weeks or until wound closure, whichever is sooner.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care, Diabetic Foot Ulcers
Description: Advanced wound care dressings and offloading applied daily for a period of 8 weeks or until wound closure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care, Diabetic Foot Ulcers
Description: Advanced wound care dressings and offloading applied daily for a period of 8 weeks or until wound closure
Study: NCT00305084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: 0.2, 0.4, 0.8 and 1.6 μg/m²as 60-minute intravenous infusion every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion)
Study: NCT02857257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACHIM
Description: After an observation period of 4 weeks patients with IBS-D will be treated with ACHIM
Study: NCT04071210

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic tablet
Description: Probiotic tablet twice a day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet twice a day for 12 weeks
Study: NCT02694926

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: During a session of 90 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings.
Study: NCT01057810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
Study: NCT00747019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prosocial Behavior Physical Activity (PBPA)
Description: The PBPA condition involves a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9. PBPA participants also earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise (PE)
Description: The PE condition is a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9.
Study: NCT03417349

Intervention type: DEVICE
Intervention: Sofia
Description: The SOFIA™/ SOFIA™ PLUS Catheter will be used in removal/aspiration of emboli and thrombi following the CE marked Instructions For Use. Enrollment into the study does not change the routine care at the site provided to the patient requiring mechanical thrombectomy treatment.
Study: NCT01541956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Description: Vildagliptin 50 mg twice daily
Study: NCT00437151

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: More frequent than normal office visits
Description: Mode of patient reminder
Study: NCT02299232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Drug: dexmedetomidine 100 mcg/mL was applied in 3 mcg/kg and 4 mcg/kg doses in 1 mL preperates, 0.5 mL for each nostril
Study: NCT00437151

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic reminders (voice, e-mail, text messages)
Description: Mode of patient reminder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral involvement / intervention reminders
Description: Mode of patient reminder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention or reminders
Description: Mode of patient reminder
Study: NCT04996810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROTOXIN
Description: Botulinum toxin Type A

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botox®
Description: Botulinum toxin Type A
Study: NCT01847573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: May be administered in either fed or fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: May be administered in either fed or fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: May be administered in either fed or fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: May be administered in either fed or fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: May be administered in either fed or fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: May be administered in either fed or fasted state
Study: NCT01617564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bipuvacain
Description: PCB with 20ml bupivakain or sodium cloride 9mg/ml will be administered one hour following misorpostol administration (first dose).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: NaCl
Description: PCB with 20ml sodium chloride (9mg/ml) inactive (sham) comparator
Study: NCT01403350

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Malaria Rapid Diagnostic test
Description: Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
Study: NCT04443322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab Injection
Description: Anti-PD-L1 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 4 MG
Description: Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β etc.
Study: NCT02588768

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation therapy (Phototherapy)
Description: PBMT was applied employing MR4 Laser Therapy Systems manufactured by Multi Radiance Medical, Solon - OH, USA. The cluster emitter contains 12 diodes with four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode). It was applied in direct contact with the skin to 9 sites on extensor muscles of the knee, 6 sites on knee flexors of the knee, and 2 sites on the calf of both lower limbs. To ensure blinding, the device emitted the same sounds and regardless of the programmed mode (active or placebo).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation therapy (Phototherapy)
Description: PBMT was applied employing MR4 Laser Therapy Systems manufactured by Multi Radiance Medical, Solon - OH, USA. The cluster emitter contains 12 diodes with four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode). It was applied in direct contact with the skin to 9 sites on extensor muscles of the knee, 6 sites on knee flexors of the knee, and 2 sites on the calf of both lower limbs. To ensure blinding, the device emitted the same sounds and regardless of the programmed mode (active or placebo).
Study: NCT01754350

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calorie-restricted ketogenic diet and transient fasting
Description: On day 1-3 and day 7-9, restriction of carbohydrates to \< 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by Tavarlin.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard nutrition
Description: nutrition as recommended by the german society for nutrition, 30 kcal/kg per day
Study: NCT01781845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AFRI-SVI Ultrasound
Description: This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI)a new ultrasound technology in which unique sound waves create the images/pictures of the kidney beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
Study: NCT04397016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Option Grid Decision Aid
Description: -A table with side-by-side comparisons of treatment options organized as responses to patients' frequently asked questions